OBJECTIVES: HSCT is an accepted and efficacious treatment option in second or later line treatment of ALL/DLBCL/FL patients. We describe direct medical costs and healthcare resource utilization (HRU) for HSCT in ALL/DLBCL/FL patients in Japan.

METHODS: This study employed Japanese claims data of patients who received alloHSCT/autoHSCT between Jan-2012 and Sep-2017. Using a Japanese payer perspective, costs were evaluated from the index hospitalization and up to 5 years after.

RESULTS: Costs data from 91 adult ALL/DLBCL/FL patients (mean age: 45±13 years) receiving an alloHSCT were included. HRU was highest in the 1^st-year with a mean of 124±58 inpatient days and 26±11 outpatient visits. Total medical cost during the 1^st-year was ¥13.3±5.0 million with index hospitalization cost of ¥11.1±6.8 million. Costs data from pediatric ALL/DLBCL patients (n=23; mean age: 9±6 years) receiving alloHSCT demonstrated a similar trend with total medical cost during the 1^st-year of 12.1±3.3 million and index hospitalization cost of ¥12.3±5.6 million (index hospitalization may last longer than that of 1^st-year). Costs data from 62 adult ALL/DLBCL/FL patients (mean age: 54±11 years) receiving autoHSCT were included. HRU was highest in the 1^st-year with a mean of overall 52±38 inpatient days and 25±12 outpatient visits. Total medical cost during the 1^st-year was ¥5.3±2.8 million with index hospitalization cost of ¥3.9±2.6 million. For all HSCT receiving patients, inpatient admissions decreased after the 1^st-year. Patients continued to report high number of outpatient visits in subsequent years, not all of which may be directly related to HSCT. Inpatient stay and prescription drug costs were identified as the main overall cost-drivers.

CONCLUSIONS: Patients undergoing HSCT incur significant medical costs during the 1^st-year of treatment, largely driven by inpatient stay and drug costs. These findings are in line with the high costs reported elsewhere. Patients also had frequent outpatient visits and resource utilization in the years following HSCT.